Authors

Deborah Neesham

Email: Neeshamd@ramsayhealth.com.au

MBBS (Melb), DCH (London), FRANZCOG, CGO, Consultant Gynaecological Oncologist, The Women’s Hospital, Frances Perry House, Vic


Advances in epithelial ovarian cancer

Molecular targeting agents are revolutionising treatment options, particularly poly adenosine diphosphate–ribose polymerase inhibitors, especially for patients with an underlying BRCA mutation.